Tag: anti-PD-L1

1. In this retrospective cohort study investigating targeted therapy of programmed cell death receptor 1 and programmed cell death ligand 1 in the treatment of microsatellite stable (MSS) metastatic colorectal cancer with and without liver metastases, targeted therapy was found to be effective in patients without liver metastases, but...
1. Overall survival and progression-free survival were higher for patients on nivolumab plus chemotherapy compared to chemotherapy alone. 2. Severe adverse events occurred more frequently in the nivolumab group and more patients withdrew from treatment due to these events. Evidence Rating Level: 1 (Excellent) Study Rundown: The 5-year survival rate of patients...
Click to read the study in The Lancet Oncology. Click to see previously reported survival outcomes from the same cohort.
1. Median overall survival and progression-free survival were significantly improved with cemiplimab monotherapy compared to chemotherapy. 2. Patients treated with cemiplimab monotherapy reported fewer grade 3-4 adverse events.  Evidence Rating Level: 1 (Excellent) Study Rundown: Among patients with advanced non-small-cell lung cancer (NSCLC), a large proportion test positive for programmed cell death...